REPL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
REPL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Replimune Group's other current assets for the quarter that ended in Dec. 2023 was $8.52 Mil.
Replimune Group's quarterly other current assets increased from Jun. 2023 ($7.89 Mil) to Sep. 2023 ($8.51 Mil) and increased from Sep. 2023 ($8.51 Mil) to Dec. 2023 ($8.52Mil).
Replimune Group's annual other current assets increased from Mar. 2021 ($4.49 Mil) to Mar. 2022 ($5.27 Mil) increased from Mar. 2022 ($5.27 Mil) to Mar. 2023 ($6.28 Mil).
The historical data trend for Replimune Group's Other Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Replimune Group Annual Data | ||||||||||||||||
Trend | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | Mar23 | |||||||||
Other Current Assets | Get a 7-Day Free Trial | 3.70 | 2.73 | 4.49 | 5.27 | 6.28 |
Replimune Group Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Other Current Assets | Get a 7-Day Free Trial | 5.59 | 6.28 | 7.89 | 8.51 | 8.52 |
Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:
The assets grouped under other current assets are most commonly:
Some companies can and do choose to report each of these items separately.
Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.
Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.
Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.
Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.
There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.
At most companies, other current assets are a small and unimportant part of the total balance sheet.
Thank you for viewing the detailed overview of Replimune Group's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher Sarchi | officer: Chief Commercial Officer | C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801 |
Konstantinos Xynos | officer: Chief Medical Officer | C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801 |
Emily Luisa Hill | officer: Chief Financial Officer | C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
Pamela Esposito | officer: Chief Business Officer | C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801 |
Sushil Patel | officer: Chief Commercial Officer | C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801 |
Tanya Lewis | director | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459 |
Veleka Peeples-dyer | director | C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801 |
Andrew Schwendenman | officer: Chief Accounting Officer | C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801 |
Philip Astley-sparke | director, 10 percent owner, officer: Executive Chairman | C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801 |
Robert Coffin | director, 10 percent owner, officer: President and C.E.O. | C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801 |
Love Colin | 10 percent owner, officer: Chief Operating Officer | C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 10801 |
Jean M. Franchi | officer: Chief Financial Officer | C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Omega Fund Iv Gp, L.p. | 10 percent owner | 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
Christy J. Oliger | director | 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459 |
Jason P Rhodes | director | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
From GuruFocus
By sperokesalga sperokesalga • 05-18-2023
By Marketwired • 08-03-2023
By Value_Insider Value_Insider • 12-09-2022
By Marketwired • 11-07-2023
By Value_Insider Value_Insider • 11-23-2022
By sperokesalga sperokesalga • 06-01-2023
By Stock market mentor Stock market mentor • 01-04-2023
By Marketwired • 09-19-2023
By Stock market mentor Stock market mentor • 01-04-2023
By Marketwired • 08-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.